Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Interest Expenses (2016 - 2025)

Rocket Pharmaceuticals' Interest Expenses history spans 9 years, with the latest figure at $473000.0 for Q4 2025.

  • For Q4 2025, Interest Expenses changed 0.0% year-over-year to $473000.0; the TTM value through Dec 2025 reached $1.9 million, changed 0.27%, while the annual FY2025 figure was $1.9 million, 0.27% changed from the prior year.
  • Interest Expenses for Q4 2025 was $473000.0 at Rocket Pharmaceuticals, roughly flat from $473000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.7 million in Q1 2021 and bottomed at $251000.0 in Q2 2021.
  • The 5-year median for Interest Expenses is $470500.0 (2023), against an average of $524500.0.
  • The largest annual shift saw Interest Expenses plummeted 85.95% in 2021 before it soared 85.26% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $463000.0 in 2021, then grew by 0.86% to $467000.0 in 2022, then grew by 0.64% to $470000.0 in 2023, then rose by 0.64% to $473000.0 in 2024, then changed by 0.0% to $473000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Interest Expenses are $473000.0 (Q4 2025), $473000.0 (Q3 2025), and $473000.0 (Q2 2025).